We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sequenom Announces Multiple MassARRAY Systems Sales in China
News

Sequenom Announces Multiple MassARRAY Systems Sales in China

Sequenom Announces Multiple MassARRAY Systems Sales in China
News

Sequenom Announces Multiple MassARRAY Systems Sales in China

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sequenom Announces Multiple MassARRAY Systems Sales in China"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sequenom, Inc., a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, today announced the sales of multiple MassARRAY(R) systems in China. Sequenom's new MassARRAY customers include the Beijing Genomics Institute (BGI), Asia's largest genetic sequencing center, which plans to initially use the system for its advanced research in viral genetics and later for human genetic projects, and CapitalBio, a leading China-based life science service company with capacities for whole genome association studies, which plans to expand into the fine mapping market.

Dr. Wang Wei, BGI Director of Viral Genotyping, said, "We chose Sequenom's MassARRAY technology because it features a unique combination of through-put, accuracy, sensitivity, reproducibility and cost efficiency. It is particularly suitable for the high-volume viral genotyping project and other population screening projects we plan to undertake in the near future."

Sequenom's President and CEO Harry Stylli, Ph.D. said, "We view the Chinese market as a very attractive opportunity to expand our genetic analysis business. We believe that sales to the distinguished research institute BGI and a leading service provider CapitalBio demonstrate the effectiveness of our activities to penetrate the growing Chinese market."

Advertisement